University of Southern California

USC News logo

Moving Targets Takes Aim at Diabetes

08/29/08
Annual School of Pharmacy symposium draws scientists and students from across the country.
By Kukla Vera
Ph.D. students Robert Mo and Janette Contreras were among the event organizers.

Diabetes, one of the world’s greatest health challenges, was the focus of the 2008 “Moving Targets” symposium hosted by the USC School of Pharmacy Aug. 22 in Pasadena.

“Moving Targets: Diabetes: Mechanisms and Treatments” included two featured presentations by renowned diabetes experts.

George L. King, director of research at the Joslin Diabetes Center in Boston, discussed the development of PKC inhibitors as therapeutic agents for diabetic complications and John Patton, chief scientific fellow and co-founder of Nektar Therapeutics, presented an overview on inhaled insulin.

Richard Bergman, chair of physiology and biophysics at the Keck School of Medicine of USC, presented a talk on metabolic syndrome and diabetes.

The event attracted some 130 students, faculty, clinicians and industry representatives. Students came from USC, the University of California, Irvine, the University of California, San Diego and Stanford University. The event provides a unique environment for the attendees to network as well as participate in the scientific sessions.

Janette Contreras, a Ph.D. student at the School of Pharmacy, was the podium host throughout the day. Contreras is chair of the group that sponsors the annual event, the USC Student Chapter of the American Association of Pharmaceutical Scientists.

The lecture portion of the program was followed by the “Moving Targets Student Poster Competition." This year’s first-place honor went to Nazanin Yacobi, a Ph.D. student at the Keck School of Medicine. Second place went to Jennifer-Ann Bayan, a Ph.D. student at the School of Pharmacy and third place was awarded to Eszter Pais, a Ph.D. student at Keck.

Support for “Moving Targets 2008” was provided by the USC School of Pharmacy, the American Association of Pharmaceutical Scientists, Allergan and Pfizer.